Quick Answer
Evofem Biosciences, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $19.36 million for the year ending 2024.
- Evofem Biosciences, Inc. showed an increase of +6.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2023 to 2024.
- This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $4.25 million | Q2 2022: $6.03 million | Q3 2022: $6.37 million | Q1 2023: $5.81 million | Q2 2023: $2.46 million | Q3 2023: $5.11 million | Q1 2024: $3.60 million | Q2 2024: $4.16 million | Q3 2024: $4.50 million | Q1 2025: $845.0 thousand | Q2 2025: $4.83 million | Q3 2025: $4.95 million.
- Over the full 3 years of available data (2022 to 2024), Evofem Biosciences, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 15.0%.
- Historical annual values: Fiscal year 2024: $19.36 million | Fiscal year 2023: $18.22 million | Fiscal year 2022: $16.84 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: